Halozyme Therapeutics (HALO) Leerink Global Healthcare Conference 2026 summary

Strategic growth and acquisitions

• Expanded ENHANZE collaborations and completed acquisitions of Elektrofi and Surf Bio, diversifying offerings in subcutaneous drug delivery and enabling entry into small-volume, at-home treatments.

• Hypercon and Surf Bio technologies allow biologics to be concentrated 3x-4x, reducing injection volumes to 2 mL or less for autoinjector compatibility.

• Hypercon is more advanced, expected to enter clinical trials this year, while Surf Bio is targeting late 2027 or early 2028 for clinical entry.

• Ongoing discussions with multiple partners across all technologies, broadening the addressable market and strategic fit.

• Disciplined M&A approach focused on recurring, royalty-like revenue opportunities, with a strong balance sheet and plans for further acquisitions if aligned with the business model.

Technology differentiation and pipeline expansion

• ENHANZE enables large-volume subcutaneous delivery, with 10 approved products and six new clinical study starts projected this year.

• Hypercon uses dehydration to create stable, highly syringeable oil-based solutions for monoclonal antibodies and antibody-drug conjugates.

• Surf Bio employs a polymer-based, spray-dried particle approach, with more work done on small molecules.

• Expectation to double the number of commercialized and development products from 20 to 40 by 2028, driven by strong partner interest in subcutaneous delivery.

• Pipeline includes blockbusters like DARZALEX, VYVGART, Opdivo, TECENTRIQ, OCREVUS, and RYBREVANT, all showing strong growth and uptake with subcutaneous formulations.

Financial performance and guidance

• 2025 revenue grew 38% to $1.4 billion, with royalties up 52%.

• Fourth quarter EPS was below consensus due to a one-time charge from the Surf Bio acquisition, not recurring.

• Guidance projects continued strong royalty-driven growth, with new launches and expanded reimbursement expected to boost contributions from key products.

• Net debt to EBITDA expected to decrease from 3x to 1x by year-end if no further acquisitions occur.